Other substances

Tipranavir

An HIV protease inhibitor.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

6
 Supporting references
0
 Contradictory references
8
 AI-suggested references
0
 Clinical trials

General information

Tipranavir is a non-peptidomimetic inhibitor of human immunodeficiency virus (HIV) protease (NCIt).

Tipranavir on DrugBank
Tipranavir on PubChem
Tipranavir on Wikipedia

Marketed as

APTIVUS

 

Structure image - Tipranavir

CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4

Supporting references

Link Tested on Impact factor Notes Publication date
Discovering drugs to treat coronavirus disease 2019 (COVID-19).
in silico Feb/22/2020
Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro
Preprint 		VERO E6 cell cultures Apr/08/2020
Systemic in Silico Screening in Drug Discovery for Coronavirus Disease (COVID-19) with an Online Interactive Web Server
in silico 4.55

Predicted to bind a SARS-CoV-2 protein structural feature.

 Aug/11/2020
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
in silico 3.31

In silico screening of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors.

 Aug/05/2020
Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach
3CLpro RdRpol Small molecule In silico 		in silico 2.45

Predicted to bind both SARS-CoV-2 3C-like protease and RNA-dependent RNA polymerase. It also possesses predicted good bioavailability.

 Oct/26/2020
Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents
3CLpro Small molecule Enzyme assay In vitro In silico 		in silico; in vitro enzyme assay

Partialy inhibits (IC50 of 27.7 µM; 64% inhibition at 50 µM) the SARS-CoV-2 3C-like protease in vitro.

 Jan/20/2021

AI-suggested references

Link Publication date
Multidomain drug delivery systems of beta-casein micelles for the local oral co-administration of antiretroviral combinations.
Aug/22/2021
Design, synthesis and in silico screening of benzoxazole-thiazolidinone hybrids as potential inhibitors of SARS-CoV-2 proteases
Dec/24/2021
SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)
Jul/09/2020
Drug binding dynamics of the dimeric SARS-CoV-2 main protease, determined by molecular dynamics simulation
Aug/03/2021
Prioritisation of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Jun/14/2020
In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling
Feb/18/2021
Dual inhibitors of SARS-CoV-2 proteases: pharmacophore and molecular dynamics based drug repositioning and phytochemical leads
May/30/2020
In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing
Jun/16/2020
Export (.csv)